Medicinal chemistry strategies targeting NLRP3 inflammasome pathway: A recent update from 2019 to mid-2023

被引：16

作者：

Duan, Meibo ^{[1
]}

Sun, Lei ^{[1
]}

He, Xinzi ^{[1
]}

Wang, Zechen ^{[1
]}

Hou, Yunlei ^{[1
]}

Zhao, Yanfang ^{[1
]}

机构：

[1] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, 103 Wenhua Rd, Shenyang 110016, Peoples R China

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 260卷

关键词：

NLRP3; inhibitors; Inflammatory disease; Structure-activity relationships; POTENTIAL TREATMENT; GASDERMIN D; ACTIVATION; INHIBITOR; IDENTIFICATION; DERIVATIVES; CASPASE-1; RECEPTORS; MECHANISM; FIBROSIS;

D O I：

10.1016/j.ejmech.2023.115750

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Nod-like receptor protein 3 (NLRP3), a therapeutic target that has a close relationship with inflammatory diseases, has drawn significant attention from researchers in the field. An increasing number of NLRP3 inhibitors have been reported since NLRP3 was identified as a biomarker and inflammatory therapeutic target. Inhibiting NLRP3 has been widely studied as therapeutics for the treatment of cryopyrin associated periodic syndrome (CAPS), inflammatory bowel disease (IBD), nonalcoholic steatohepatitis (NASH), arthrolithiasis, Alzheimer's disease (AD) and Parkinson's disease (PD). This review updates the recently reported (2019 to mid-2023) molecule inhibitors targeting the NLRP3 inflammasome pathway, summarizes their structure-activity relationships (SARs), and discusses the therapeutic effects on inflammatory diseases. I hope this review will contribute to the development of novel inhibitors targeting NLRP3 inflammasome pathway as potential drugs.

引用

页数：22

共 123 条

[1] Discovery of N-Cyano-sulfoximineurea Derivatives as Potent and Orally Bioavailable NLRP3 Inflammasome Inhibitors [J].

Agarwal, Sameer ;

Sasane, Santosh ;

Shah, Hardik A. ;

Pethani, Jignesh P. ;

Deshmukh, Prashant ;

Vyas, Vismit ;

Iyer, Pravin ;

Bhavsar, Harsh ;

Viswanathan, Kasinath ;

Bandyopadhyay, Debdutta ;

Giri, Poonam ;

Mahapatra, Jogeswar ;

Chatterjee, Abhijit ;

Jain, Mukul R. ;

Sharma, Rajiv .

ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (04) :414-418

[2] Novel Aryl Sulfonamide Derivatives as NLRP3 Inflammasome Inhibitors for the Potential Treatment of Cancer [J].

Albanese, Valentina ;

Missiroli, Sonia ;

Perrone, Mariasole ;

Fabbri, Martina ;

Boncompagni, Caterina ;

Pacifico, Salvatore ;

De Ventura, Tiziano ;

Ciancetta, Antonella ;

Dondio, Giulio ;

Kricek, Franz ;

Pinton, Paolo ;

Guerrini, Remo ;

Preti, Delia ;

Giorgi, Carlotta .

JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (07) :5223-5241

[3] Preservation of Contractile Reserve and Diastolic Function by Inhibiting the NLRP3 Inflammasome with OLT1177(R) (Dapansutrile) in a Mouse Model of Severe Ischemic Cardiomyopathy Due to Non-Reperfused Anterior Wall Myocardial Infarction [J].

Aliaga, Joseph ;

Bonaventura, Aldo ;

Mezzaroma, Eleonora ;

Dhakal, Yogesh ;

Mauro, Adolfo Gabriele ;

Abbate, Antonio ;

Toldo, Stefano .

MOLECULES, 2021, 26 (12)

[4] NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation [J].

Andreeva, Liudmila ;

David, Liron ;

Rawson, Shaun ;

Shen, Chen ;

Pasricha, Teerithveen ;

Pelegrin, Pablo ;

Wu, Hao .

CELL, 2021, 184 (26) :6299-+

[5] Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression [J].

Bauernfeind, Franz G. ;

Horvath, Gabor ;

Stutz, Andrea ;

Alnemri, Emad S. ;

MacDonald, Kelly ;

Speert, David ;

Fernandes-Alnemri, Teresa ;

Wu, Jianghong ;

Monks, Brian G. ;

Fitzgerald, Katherine A. ;

Hornung, Veit ;

Latz, Eicke .

JOURNAL OF IMMUNOLOGY, 2009, 183 (02) :787-791

[6] Development of covalent NLRP3 inflammasome inhibitors: Chemistry and biological activity [J].

Bertinaria, Massimo ;

Gastaldi, Simone ;

Marini, Elisabetta ;

Giorgis, Marta .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2019, 670 :116-139

[7]

biospace, Inflazome announces acquisition by Roche

[8] The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases [J].

Blevins, Hallie M. ;

Xu, Yiming ;

Biby, Savannah ;

Zhang, Shijun .

FRONTIERS IN AGING NEUROSCIENCE, 2022, 14

[9] PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy [J].

Bonomi, Marcelo ;

Blakaj, Dukagjin M. ;

Kabarriti, Rafi ;

Colvett, Kyle ;

Takiar, Vinita ;

Biagioli, Matthew ;

Bar -Ad, Voichita ;

Goyal, Sharad ;

Muzyka, Brian ;

Niermann, Kenneth ;

Abrouk, Nacer ;

Oronsky, Bryan ;

Reid, Tony ;

Caroen, Scott ;

Sonis, Stephen ;

Sher, David J. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 116 (03) :551-559

[10] Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in Rats [J].

Caroen, Scott ;

Oronsky, Bryan ;

Reid, Tony ;

Pandher, Karamjeet ;

Lopez, Alric .

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2022, 19 (11) :1628-1630

← 1 2 3 4 5 6 7 8 9 10 →